{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:28:29Z","timestamp":1784046509608,"version":"3.55.0"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Separation Science"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    A novel high\u2010performance liquid chromatography method for the enantioseparation of mirabegron (\n                    <jats:italic>R<\/jats:italic>\n                    \u2010mirabegron), a selective \u03b2\u20103 adrenergic receptor agonist, using cyclodextrin (CD)\u2010based chiral stationary phases (CSPs) was developed. Seven different CSPs containing \u03b2\u2010, \u03b3\u2010, hydroxypropyl\u2010\u03b2\u2010, sulfobutyl\u2010\u03b2\u2010, carboxymethyl\u2010\u03b2\u2010, permethyl\u2010\u03b2\u2010, and phenylcarbamate\u2010\u03b2\u2010cyclodextrin were evaluated under both polar organic and reversed\u2010phase conditions. Only the phenylcarbamate\u2010\u03b2\u2010cyclodextrin containing the Chiral CD\u2010Ph column displayed enantiorecognition. Optimization of conditions using a full factorial design led to the determination of the most suitable conditions: a mobile phase composition of 90:10:0.1 methanol:water:diethylamine, a flow rate of 0.8\u00a0mL\/min, and a column temperature of 40\u00b0C with enantiomeric elution order, where the impurity\n                    <jats:italic>S<\/jats:italic>\n                    \u2010mirabegron elutes first. Using the optimized conditions, enantioseparation with\n                    <jats:italic>R<\/jats:italic>\n                    <jats:sub>s<\/jats:sub>\n                    = 1.9 was achieved within 10 min. The developed method was validated according to current guidelines and successfully applied for the determination of\n                    <jats:italic>S<\/jats:italic>\n                    \u2010mirabegron, as a chiral impurity in pharmaceutical formulations. The enantiorecognition mechanism was investigated by molecular docking and thermodynamic analysis. Using molecular modeling, the interactions between CDs and the analyte were analyzed at the molecular level, revealing that mirabegron interacts primarily with the phenylcarbamate groups on the outer surface of the structure. Enthalpy\u2010controlled enantioseparation was consistently observed across all eluent compositions, regardless of the conditions. The developed and validated method is highly suitable for routine determination of the enantiomeric purity of mirabegron, offering a reliable tool for regulatory compliance.\n                  <\/jats:p>","DOI":"10.1002\/jssc.70132","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:21:41Z","timestamp":1744244501000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Enantioseparation of Mirabegron Using Cyclodextrin\u2010based Chiral Columns: High\u2010performance Liquid Chromatography and Molecular Modeling Study"],"prefix":"10.1002","volume":"48","author":[{"given":"Ali","family":"Mhammad","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry Semmelweis University  Budapest Hungary"},{"name":"Center for Pharmacology and Drug Research &amp; Development Semmelweis University  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Dombi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry Semmelweis University  Budapest Hungary"},{"name":"Center for Pharmacology and Drug Research &amp; Development Semmelweis University  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1t\u00e9","family":"Dob\u00f3","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry Semmelweis University  Budapest Hungary"},{"name":"Center for Pharmacology and Drug Research &amp; Development Semmelweis University  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n\u2010Istv\u00e1n","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"George Emil Palade University of Medicine, Pharmacy Science, and Technology of Targu Mures  Targu Mures Romania"},{"name":"Sz\u2010imfidum Ltd  Lunga Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Fiser","sequence":"additional","affiliation":[{"name":"Institute of Chemistry University of Miskolc  Miskolc Hungary"},{"name":"Department of Biology and Chemistry Ferenc R\u00e1k\u00f3czi II Transcarpathian Hungarian College of Higher Education  Transcarpathia Ukraine"},{"name":"Department of Physical Chemistry Faculty of Chemistry University of Lodz  Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerg\u0151","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry Semmelweis University  Budapest Hungary"},{"name":"Center for Pharmacology and Drug Research &amp; Development Semmelweis University  Budapest Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/app122110909"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.2c04371"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.6073"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1134\/S1061934823030048"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRAC.2019.115639"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202400148"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRAC.2024.117708"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/CHROMSCI\/22.9.411"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.4820"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.201800132"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/JSSC.200700047"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010023\u201041941\u20105"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287212457114"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22373"},{"key":"e_1_2_6_16_1","unstructured":"European Pharmacopoeia.Mirabegron Monograph.2023."},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2016.1144201"},{"key":"e_1_2_6_18_1","first-page":"1841","article-title":"Structure Identification of the Main Degradation Products of Mirabegron\u2217","volume":"36","author":"Wang Y.","year":"2016","journal-title":"Chinese Journal of Pharmaceutical Analysis"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10337\u2010016\u20103210\u20101"},{"key":"e_1_2_6_20_1","first-page":"1439","article-title":"Determination of Related Substances in Mirabegron by HPLC","volume":"36","author":"Ding Y.","year":"2016","journal-title":"Chinese Journal of Pharmaceutical Analysis"},{"issue":"1","key":"e_1_2_6_21_1","first-page":"78","article-title":"Method Development and Validation of Mirabegron in Bulk Drug and Pharmaceutical Dosage Form","volume":"13","author":"Jyothsna M.","year":"2018","journal-title":"IOSR Journal of Pharmacy and Biological Sciences"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.22159\/ijcpr.2017v9i5.22158"},{"key":"e_1_2_6_23_1","first-page":"36","article-title":"RP\u2010HPLC Method Development and Validation for the Quantitative Estimation of Mirabegron in Extended\u2010Release Tablets","volume":"1","author":"Rezaei M.","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.13040\/Ijpsr.0975\u20108232.11(5).2223\u201028"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806\u20109282.65.2.141"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.02.007"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CHROMA.2015.06.051"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23051065"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jctc.5b00864"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/JCC.21334"},{"key":"e_1_2_6_31_1","unstructured":"European Medicinal Agency.Validation of Analytical Procedures\u2014Scientific Guideline. ICH Q2 (R2). 2024 EMA\/CHMP\/ICH\/82072\/2006."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CHROMA.2009.10.022"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2014.06.087"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/elps.201800194"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826070701191193"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/JSSC.201701264"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2019.460594"}],"container-title":["Journal of Separation Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jssc.70132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:15:13Z","timestamp":1763201713000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jssc.70132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/jssc.70132"],"URL":"https:\/\/doi.org\/10.1002\/jssc.70132","archive":["Portico"],"relation":{},"ISSN":["1615-9306","1615-9314"],"issn-type":[{"value":"1615-9306","type":"print"},{"value":"1615-9314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70132"}}